DBCO-PEG4-VA-PBD

DBCO-PEG4-VA-PBD is a potent ADC Cytotoxin with Linker, comprising the DNA-crosslinking PBD (pyrrolobenzodiazepine) payload linked via a cleavable VA-PAB ADC Linker and a PEG4 spacer. The construct maintains stability in circulation while enabling selective intracellular release of the ADC payload in antigen-expressing tumor cells. As a defined ADC Cytotoxin, DBCO-PEG4-VA-PBD delivers the PBD payload efficiently, inducing DNA minor-groove crosslinking and apoptosis with predictable intracellular activation.

The mechanism of DBCO-PEG4-VA-PBD involves antibody-mediated binding to tumor-associated antigens and internalization into target cells. Once inside lysosomes, the VA-PAB linker is cleaved by proteases, releasing the PBD payload. This targeted release ensures the ADC payload exerts its DNA-crosslinking cytotoxic activity specifically in tumor cells, maintaining potent efficacy while limiting systemic exposure. The PEG4 spacer enhances solubility and provides flexibility for efficient conjugation.

DBCO-PEG4-VA-PBD supports stable conjugation to antibodies through its DBCO functional group, producing homogeneous ADC Cytotoxins with Linker. The cleavable VA-PAB linker and PEG4 spacer ensure consistent intracellular payload release and reproducible cytotoxic performance. Its chemical properties, including solubility, linker stability, and predictable cleavage, enable reliable ADC assembly and precise intracellular delivery of the PBD payload in antigen-positive cells.

Applications of DBCO-PEG4-VA-PBD focus on its role as a defined ADC payload-linker combination for constructing homogeneous antibody-drug conjugates. The protease-sensitive linker and PEG4 spacer provide controlled intracellular release of PBD, producing consistent DNA crosslinking and cytotoxicity. This reagent delivers potent, targeted effects in ADC Cytotoxins with Linker, supporting precise and reliable cytotoxic payload delivery in oncology applications.